BiDil Survival Benefit Precludes Need For Component Efficacy Evaluation

NitroMed's BiDil demonstration of a survival benefit in African-Americans with heart failure makes moot an investigation into the safety and efficacy of the combination drug's individual components, an FDA advisory committee agreed